Clinical trial · Observational
Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
A Multicentre Prospective Study Investigating the Utility of ctDNA as a Biomarker of Disease Burden, Genetic Heterogeneity and Tumour Evolution in Advanced Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sample collection only | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Cohort 1
- description
- Patients with newly diagnosed iodine refractory thyroid cancer on surveillance
- interventionNames
- Other: Sample collection only
- label
- Cohort 2
- description
- Patients with locally advanced and / or metastatic (Stage 3 \& 4) medullary thyroid cancer
- interventionNames
- Other: Sample collection only
- label
- Cohort 3
- description
- Patients with iodine refractory thyroid cancer or advanced/metastatic unresectable MTC due to commence systemic treatment or already on systemic treatment
- interventionNames
- Other: Sample collection only
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older. (all cohorts) * Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1) * Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2) * Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3) * Patients with newly diagnosed anaplastic thyroid cancer (cohort 4) * Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts) * Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts) * Ability to give informed consent for biological sample collection. (all cohorts) Exclusion Criteria: * Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection * Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ) * Pregnancy
References
Publications (0)
Data not yet available